Healthcare data company ConcertAI has announced a multi-year agreement with pharmaceutical and biotechnology giant Bayer to utilize ConcertAI's Translational360 and AI SaaS offerings. The partnership aims to accelerate clinical development in precision oncology by leveraging AI- and machine learning-acquired insights.

The collaboration will utilize ConcertAI's Translational360, an integrated research-level longitudinal clinical molecular database that harnesses the CancerLinQ network of anonymized cancer patient data. This extensive resource includes more than 9 million patient records from all 50 states, offering a comprehensive view of cancer care across the United States.

What makes Translational360 particularly valuable is its integration of "clinical, genomic, transcriptomic and whole-slide imaging from comprehensive molecular testing for deep phenotypical and genomic insights." The transcriptomic capabilities allow researchers to understand disease molecular mechanisms, the basis of patient response, and inter-patient flexibility—factors crucial for developing effective new therapeutics.

By combining integrated data solutions with artificial intelligence, the partnership aims to select programs with the highest probability of success and design trials influenced by multimodal, multi-genomic and transcriptomic data and AI analytics.

"This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modeling of likely success and benefit, informing program priority and clinical study design," Jeff Elton, CEO of ConcertAI, said in a statement.

The agreement represents the latest development in ConcertAI's expansion of partnerships and capabilities. In 2023, the company expanded its collaboration with Caris Life Sciences to jointly create a database generating insights to advance precision medicine, clinical trial management, and therapeutic development. The previous year, ConcertAI secured $150 million in Series C funding, which valued the company at $1.9 billion.

Meanwhile, Bayer has been actively pursuing AI partnerships across healthcare. In 2024, the company collaborated with GenAI radiology workflow company Rad AI to bring its technology to Bayer's Calantic Digital Solution customers. That same year, Bayer also partnered with Google Cloud to develop AI applications aimed at reducing radiologist burnout and increasing efficiencies in diagnoses, leveraging Google Cloud's generative AI tools, Vertex AI, BigQuery, Healthcare API, and Chronicle.

This latest partnership between ConcertAI and Bayer represents a significant step forward in applying artificial intelligence to accelerate drug development and improve outcomes for cancer patients through more precise treatment approaches.

Click here for the original news story.